Document Detail

Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9.
MedLine Citation:
PMID:  20166242     Owner:  NLM     Status:  MEDLINE    
Glioblastoma multiforme remains one of the most devastating human malignancies because of its high infiltrative capacity. This study aimed to investigate the effects of silibinin on human glioblastoma U87MG cells. The microculture tetrazolium test, bromodeoxyuridine cell proliferation assay, cell-based nuclear factor kappa B (NF-[kappa]B) activation assessment, cathepsin B activity assay, gelatin zymography, and quantitative real-time reverse transcription-PCR were performed to appraise the effects of silibinin on the metabolic activity, DNA synthesis, NF-[kappa]B phosphorylation, cathepsin B activity, and gelatinolytic activity of U87 cells. Silibinin inhibited metabolic activity, cell proliferation, NF-[kappa]B activation, cathepsin B enzymatic levels, and gelatinase B activity in U87 cells. In addition, an expressive decrease in mRNA levels of matrix metalloproteinase-9, cathepsin B, urokinase plasminogen activator receptor, urokinase plasminogen activator, and intercellular adhesion molecule 1 coupled with a significant induction in transcriptional levels of stefin A was observed. Altogether, these issues show for the first time that silibinin treatment could trammel invasive features of a highly invasive human glioma cell line, U87, through suppression of NF-[kappa]B-mediated stimulation of matrix metalloproteinase-9. Furthermore, silibinin might cripple the activation of gelatinase B by cramping transcriptional and enzymatic activities of cathepsin B in U87 cells.
Majid Momeny; Mohsen Malehmir; Majid Zakidizaji; Reza Ghasemi; Habibeh Ghadimi; Mohammad A Shokrgozar; Amir H Emami; Shahriar Nafissi; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  21     ISSN:  1473-5741     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-17     Completed Date:  2010-03-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  252-60     Citation Subset:  IM    
Hematology, Oncology and Bone Marrow Transplantation Research Center, Tehran, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Cathepsin B / antagonists & inhibitors*
Cell Line, Tumor
Cell Proliferation / drug effects
Cystatin A / metabolism
Glioblastoma / metabolism*,  pathology
Intercellular Adhesion Molecule-1 / metabolism
Matrix Metalloproteinase 9 / antagonists & inhibitors*
NF-kappa B / agonists*
Receptors, Urokinase Plasminogen Activator / metabolism
Silymarin / pharmacology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Cystatin A; 0/NF-kappa B; 0/PLAUR protein, human; 0/Receptors, Urokinase Plasminogen Activator; 0/Silymarin; 126547-89-5/Intercellular Adhesion Molecule-1; 22888-70-6/silybin; 80209-89-8/CSTA protein, human; EC B; EC Metalloproteinase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a high...
Next Document:  Mitral valve repair for functional mitral regurgitation: is annuloplasty alone enough?